OverviewSuggest Edit

Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company developing medicines for cancers that are genetically defined. The company offers AL101 and AL102 gamma-secretase inhibitors, with clinical and nonclinical studies underway in both solid tumors (AL101) and hematologic malignancies (AL102).

TypePublic
Founded2017
HQWilmington, DE, US
Websiteayalapharma.com

Latest Updates

Employees (est.) (Dec 2019)29
Revenue (FY, 2019)$2.3 M
Share Price (May 2021)$10
Cybersecurity ratingBMore

Key People/Management at Ayala Pharmaceuticals

Roni Mamluk

Roni Mamluk

CEO
Gary Gordon

Gary Gordon

Chief Medical Officer
Dana Gelbaum

Dana Gelbaum

Chief Business Officer
David Caron

David Caron

VP CMC
Joel Kaye

Joel Kaye

VP Research and Nonclinical Development
Irit Klipper-Avni

Irit Klipper-Avni

VP Human Resources
Show more

Ayala Pharmaceuticals Office Locations

Ayala Pharmaceuticals has offices in Wilmington and Rehovot
Wilmington, DE, US (HQ)
1007 N Orange St 4th floor
Wilmington, DE, US
1313 N Market St #5100
Rehovot, IL
Prof. Hillel ve-Khanan Oppenheimer St 4
Show all (3)

Ayala Pharmaceuticals Financials and Metrics

Ayala Pharmaceuticals Revenue

Ayala Pharmaceuticals's revenue was reported to be $2.33 m in FY, 2019
USD

Revenue (FY, 2019)

2.3m

Gross profit (FY, 2019)

1.0m

Gross profit margin (FY, 2019), %

44.9%

Net income (FY, 2019)

(17.8m)

EBIT (FY, 2019)

(17.7m)

Market capitalization (11-May-2021)

133.5m

Closing stock price (11-May-2021)

10.0

Cash (31-Dec-2019)

16.7m
Ayala Pharmaceuticals's current market capitalization is $133.5 m.
USDFY, 2018FY, 2019

Revenue

2.3m

Cost of goods sold

1.3m

Gross profit

1.0m

Gross profit Margin, %

45%
USDFY, 2018FY, 2019

Cash

26.1m16.7m

Accounts Receivable

469.0k

Prepaid Expenses

588.0k417.0k

Current Assets

26.9m17.7m
USDFY, 2018FY, 2019

Net Income

(8.9m)(17.8m)

Depreciation and Amortization

49.0k150.0k

Accounts Payable

818.0k1.9m

Cash From Operating Activities

(6.4m)(14.9m)
USDFY, 2018

Financial Leverage

-1.2 x
Show all financial metrics

Ayala Pharmaceuticals Acquisitions / Subsidiaries

Company NameDateDeal Size
Ayala-Oncology Israel Ltd

Ayala Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

SecurityScorecard logo

Ayala Pharmaceuticals Online and Social Media Presence

Embed Graph

Ayala Pharmaceuticals News and Updates

Ayala Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of AL102 in Combination with BCMA Targeting Agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma

REHOVOT, Israel and WILMINGTON, Del., April 21, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced the …

Ayala Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Business Update

- Completed $25 Million Strategic Financing; Extending Cash Runway into 2023

Ayala Pharmaceuticals Announces $25 Million Strategic Financing

Funding Extends Cash Runway through Multiple Expected Value Drivers Into 2023

Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of Patients with Notch-Activated Triple Negative Breast Cancer

REHOVOT, Israel and WILMINGTON, Del., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced the f…

Ayala Pharmaceuticals to Present at Noble Capital Markets 17th Annual Small & Microcap Virtual Investor Conference

REHOVOT, Israel and WILMINGTON, Del., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetica…

Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in Pivotal Phase 2/3 Study

- FDA Agreement from End-of-Phase 1 Meeting to Advance to Potential Registrational Study -
Show more

Ayala Pharmaceuticals Blogs

Ayala Pharmaceuticals to Present at the Virtual H.C. Wainwright Bioconnect Conference

REHOVOT, Israel and WILMINGTON, Del., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare... The post Ayala Pharmaceuticals to Present at…

Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

REHOVOT, Israel and WILMINGTON, Del., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare... The post Ayala Pharmaceuticals to Participat…

Ayala Pharmaceuticals Granted U.S. FDA Fast Track Designation for AL101 for the Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma

REHOVOT, Israel & WILMINGTON, Del., March 2, 2020 – (BUSINESS WIRE) – Ayala Pharmaceuticals, Inc., a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that the U.S. Food a…

Ayala Pharmaceuticals Presents Encouraging Preliminary Safety and Efficacy Data in Patients with Recurrent/Metastatic Adenoid Cystic Carcinoma with Progressing Disease and Notch Activating Mutations from Ongoing Phase 2 Clinical Trial at ESMO

- 22% Response Rate; 61% Disease Control Observed - REHOVOT, Israel & WILMINGTON, Del., September 30, 2019 – (BUSINESS WIRE) – Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with cancer, today announced …

Ayala Pharmaceuticals Announces Presentation at the European Society for Medical Oncology (ESMO)

REHOVOT, Israel & WILMINGTON, Del., September 19, 2019 – (BUSINESS WIRE) – Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers, today announced that a poster will be presented…

Ayala Pharmaceuticals to Present at 2019 Ladenburg Thalmann Healthcare Conference

REHOVOT, Israel & WILMINGTON, Del., September 17, 2019 – (BUSINESS WIRE) – Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers, today announced that Roni Mamluk, Ph.D., Chief …
Show more

Ayala Pharmaceuticals Frequently Asked Questions

  • When was Ayala Pharmaceuticals founded?

    Ayala Pharmaceuticals was founded in 2017.

  • Who are Ayala Pharmaceuticals key executives?

    Ayala Pharmaceuticals's key executives are Roni Mamluk, Gary Gordon and Dana Gelbaum.

  • How many employees does Ayala Pharmaceuticals have?

    Ayala Pharmaceuticals has 29 employees.

  • What is Ayala Pharmaceuticals revenue?

    Latest Ayala Pharmaceuticals annual revenue is $2.3 m.

  • What is Ayala Pharmaceuticals revenue per employee?

    Latest Ayala Pharmaceuticals revenue per employee is $80.5 k.

  • Who are Ayala Pharmaceuticals competitors?

    Competitors of Ayala Pharmaceuticals include Prelude Therapeutics, NextCure and tella.

  • Where is Ayala Pharmaceuticals headquarters?

    Ayala Pharmaceuticals headquarters is located at 1007 N Orange St 4th floor, Wilmington.

  • Where are Ayala Pharmaceuticals offices?

    Ayala Pharmaceuticals has offices in Wilmington and Rehovot.

  • How many offices does Ayala Pharmaceuticals have?

    Ayala Pharmaceuticals has 3 offices.